Non-enzymatic acetylation of proteins by aspirin as protection against the secondary complications of diabetes mellitus.
The non-enzymic glycosylation of proteins has been implicated as a contributing pathogenia in the secondary complications of diabetes mellitus. The reversible acetylation of proteins by aspirin could slow down the advance of the biochemical lesion in well-controlled patients. The rate of acetylation of albumin by aspirin at 37 degrees C and pH = 7.30 was found to proceed two orders of magnitude faster than the glycosylation, providing a basis for therapeutic possibilities for the complications of diabetes mellitus.
D000107:Acetylation; D001241:Aspirin / Q000494:pharmacology*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D066298:In Vitro Techniques; D010047:Ovalbumin / Q000378:metabolism*; D012709:Serum Albumin / Q000378:metabolism*
D012709:Serum Albumin; D010047:Ovalbumin; D001241:Aspirin